Orion Group (ORN) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orion Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ORN shares.
View ORN analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1-year price objectives for Orion Group's stock. Their ORN share price forecasts range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 129.0% from the stock's current price.
View analysts price targets for ORN or view top-rated stocks among Wall Street analysts.

Orion Group's stock was trading at $2.38 at the beginning of the year. Since then, ORN shares have increased by 10.1% and is now trading at $2.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ORN earnings forecast.

Orion Group Holdings, Inc. (NYSE:ORN) announced its earnings results on Monday, May, 8th. The construction company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.25. The construction company had revenue of $159.17 million for the quarter, compared to analyst estimates of $178.47 million. Orion Group had a negative trailing twelve-month return on equity of 10.36% and a negative net margin of 2.78%.

17 employees have rated Orion Group Chief Executive Officer Mark R. Stauffer on Glassdoor.com. Mark R. Stauffer has an approval rating of 58% among the company's employees. This puts Mark R. Stauffer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orion Group investors own include Pfizer (PFE), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), OPKO Health (OPK), Amarin (AMRN), AT&T (T), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Intel (INTC) and Marathon Oil (MRO).

Orion Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "ORN."

Orion Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (11.49%), Dimensional Fund Advisors LP (6.32%), Royce & Associates LP (5.81%), BlackRock Inc. (1.92%), Russell Investments Group Ltd. (1.74%) and Boston Partners (1.04%). Insiders that own company stock include Austin J Shanfelter and Mary E Sullivan.
View institutional ownership trends.

Shares of ORN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORN stock can currently be purchased for approximately $2.62.

Orion Group (NYSE:ORN) has a market capitalization of $84.29 million and generates $748.32 million in revenue each year. The construction company earns $-12,610,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

The company employs 2,447 workers across the globe.

Orion Group's mailing address is 12000 Aerospace Suite 300, Houston TX, 77034. The official website for the company is www.oriongroupholdingsinc.com. The construction company can be reached via phone at (713) 852-6500, via email at shane@stonegateinc.com, or via fax at 713-852-6530.